Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H46O |
| Molecular Weight | 326.6 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCCCCCCO
InChI
InChIKey=NOPFSRXAKWQILS-UHFFFAOYSA-N
InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
DescriptionSources: http://www.drugbank.ca/drugs/DB00632Curator's Comment: Description was created based on several sources, including
Sources: http://www.drugbank.ca/drugs/DB00632
Curator's Comment: Description was created based on several sources, including
Docosanol is a saturated 22-carbon aliphatic alcohol which exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol speeds the healing of cold sores and fever blisters on the face or lips. It also relieves the accompanying symptoms, including tingling, pain, burning, and itching. Docosanol works by inhibiting fusion between the human cell plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Unlike other cold-sore antivirals, docosanol does not act directly on the virus, and as such it is unlikely it will produce drug resistant mutants of HSV. Used for the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: HIV-1 replication |
10.0 mM [EC50] | ||
Target ID: P03200 Gene ID: 3783713.0 Gene Symbol: NA Target Organism: Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4) Sources: http://www.drugbank.ca/drugs/DB00632 |
|||
Target ID: CHEMBL2364696 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Abreva Approved UseHerpes Labialis
Topical treatment of recurrent herpes labialis (perioral herpes, cold sores, fever blisters) Launch Date2000 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.007 ng × eq/g |
25 mg/kg single, topical dose: 25 mg/kg route of administration: Topical experiment type: SINGLE co-administered: |
DOCOSANOL plasma | Oryctolagus cuniculus population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN |
|
318 ng/mL |
5 g single, oral dose: 5 g route of administration: Oral experiment type: SINGLE co-administered: |
DOCOSANOL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.02 μg × eq × h/g |
25 mg/kg single, topical dose: 25 mg/kg route of administration: Topical experiment type: SINGLE co-administered: |
DOCOSANOL plasma | Oryctolagus cuniculus population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
10 % 5 times / day steady, topical Recommended Dose: 10 %, 5 times / day Route: topical Route: steady Dose: 10 %, 5 times / day Sources: Page: 1 |
unhealthy, 18-77 years n = 370 Health Status: unhealthy Condition: Recurrent herpes simplex labialis Age Group: 18-77 years Sex: M+F Population Size: 370 Sources: Page: 1 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| n-Docosanol inhibits in vitro replication of HIV and other retroviruses. | 1996 Jan 1 |
|
| New drug approvals in 2000. | 2001 Jul-Aug |
|
| Study of detrusor dysfunction due to outlet obstruction: link between analysis of uroflows of men with benign prostatic hyperplasia and animal studies. | 2003 |
|
| Molecular transfer and transport in noncovalent microcontact printing. | 2004 Feb 3 |
|
| Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice. | 2004 Jan |
|
| Weak first-order tilting transition in monolayers of mono- and bipolar docosanol derivatives. | 2006 Nov 9 |
|
| [Studies on the chemical constituents of the aerial parts of Seseli mairei]. | 2007 Jan |
|
| Alpha-glucosidase inhibitors from Millettia conraui. | 2007 Sep |
|
| [Tadenan treatment of prostatic adenoma]. | 2009 Mar-Apr |
|
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
| An ethnobotanical survey of medicinal plants in Babungo, Northwest Region, Cameroon. | 2010 Feb 15 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
D06BB11
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
||
|
WHO-VATC |
QD06BB11
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
||
|
NCI_THESAURUS |
C281
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
661-19-8
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
DTXSID4027286
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
9G1OE216XY
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
100000088244
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
m4714
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB00632
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200453
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
940
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
C47498
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
31000
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
9G1OE216XY
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
8407
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
594680
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | RxNorm | ||
|
12620
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
5739
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
LL-43
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
SUB21986
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
DOCOSANOL
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY | |||
|
211-546-6
Created by
admin on Sat Dec 16 05:09:10 GMT 2023 , Edited by admin on Sat Dec 16 05:09:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
